Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Immunomedics (IMMU) - moderated -- Ignore unavailable to you. Want to Upgrade?

To: kdd999 who wrote (38549)	1/9/2017 1:18:42 PM
From: immuapproval	1 Recommendation Recommended By duwhee Respond to of 63307

This NEW BOD slate and pushed forward effective shareholder of record date speaks volumes to the g's current status. First they have taken a early vote re the proxy and they lose and lose big. So in response they throw out this lame slate for new bod and this will also lose. They moved the effective date of ownership forward I presume in the hopes they could do some deal with another company or investor that would buy stock and pledge their proxy votes with the g's. Problem is no one seems to what to buy immu or merge with immu. So in about 5 weeks the g's control of immu goes bye bye. This proposed bod from immu hurts the g's because it on its face Appears much weaker than the venbio slate. The market always reacts to the g's in one way.............down.